FindTrial
Sign In

CART-19 Cells for R/R B-cell Lymphoma

CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03391726
Acronym
CCFRRBL
Enrollment
20
Registered
2018-01-05
Start date
2016-01-01
Completion date
2020-12-31
Last updated
2018-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory B-cell Lymphoma

Brief summary

Relapsed/Refractory B Cell Lymphoma is a challenge to be treated, however,CART-19 cells could be very promosing. This study aims to assess the safety and toxicity of CART-19 cells for patients with relapse or refractory B cell lymphoma.

Interventions

OTHERCART-19 cells

CART-19 cells treat

Sponsors

Fujian Medical University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Signed written informed consent * Aged between 1-65 years * Patients with relapse/refractory B-cell lymphoma * Cardiac: Left ventricular ejection fraction ≥ 50% * Adequate renal and hepatic function * Performance status: Karnofsky ≥ 70%

Exclusion criteria

* Pregnant or lactating females. * Any co-morbidity precluding the administration of CART-19 cells.

Design outcomes

Primary

MeasureTime frame
Disease-free survival1 year

Secondary

MeasureTime frame
Adverse events that are related to treatment1 year

Countries

China

Contacts

Primary ContactJianda Hu, Prof.M.D.Ph.D
drjiandahu@163.com86-13959169016

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026